Assists small biotechs and larger biopharmaceutical companies
at each step of the drug development process
at each step of the drug development process
The Strategic Partnering Organization (SPO)
With its unique business model, PPRS aims to be a multi-specialist player in the healthcare industry.
PPRS has set up the following missions:
Identify
Develop
Strengthen
Propose
Therapeutic areas
- Depression, Anxiety
- Neurodegenerative diseases
- Parkinson's disease
- Sleep disorders
- Inflammatory diseases
- Sanfilippo disease
Your challenge, Our expertise
Partners letter
Lorem ipsum dolor sit amet consectetur adipisicing elitonomo seddo eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore.Lorem ipsum dolor sitmet consectetur adipisicing elitonomo seddo eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore.
Lorem ipsum dolor sitmet consectetur adipisicing elitonomo seddo eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore.
Our history
2010
Company founded
2011
5 employees
2012
4 drug projects in development
2013
”Jeune Entreprise Innovante” status granted (Young Innovative Company)
2014
US subsidiary created (Boston) , 12 employees, Direct investments in Minerva Neurosciences and V-Watch/Somno-Art
2015
26 associates (18 employees)
2016
Somno-Art Solution approved and market-ready, Successful phase II results for Minerva Neurosciences
2017
32 associates, PPRS Ventures’ first investment in Body Cap, Investigator meeting services rolled out
2018
Min-101 phase III, Smart data/ AI strategy launched, Rollout of Sleep Co services
